Tessera

Jia Luo, MD

@jia-luo.bsky.social

Thoracic medical oncologist and cancer researcher at Dana-Farber/ Harvard Cancer Center // Prev MSKCC Fellow, OHSU IM & Chief Res, Stanford Med, and UW-Madison https://t.co/Y9HwVQ1jyq

114 Posts1206 Follower 149 Folgt

Jia Luo, MD @jia-luo.bsky.social · 7mo ago

As 2025 comes to a close, I'm reflecting on the outstanding people and teams I've been lucky to work with at Dana-Farber to advance lung cancer care in the clinic and in research Look forward to a bright 2026! @danafarber.bsky.social @danafarbernews.bsky.social #lcsm

Jia Luo, MD @jia-luo.bsky.social · 8mo ago

Great to share lung cancer research updates with colleagues and friends at the 2025 IASLC NACLC meeting Thank you to chairs Drs. Bestvina, Marrone, Rengan and Gillaspie for organizing an energizing and fun conference @iaslc.bsky.social @danafarber.bsky.social #NACLC25

Jia Luo, MD @jia-luo.bsky.social · 8mo ago

1/ In JCO: PO, we describe the presentation of NUT carcinoma- it almost always presents as a poorly differentiated/ squamous lung, head and neck cancer, with a mean biopsy to diagnosis interval of 7 weeks (!) 🫁 🗣️ doi.org/10.1200/PO-2... #medsky #oncsky #lungcancer @ascocancer.bsky.social 🧵A thread:

Abstract
Purpose Diagnostic delays are common for patients with NUT carcinoma (NC), a cancer driven by NUT fusion oncoprotein. Rapid diagnosis is crucial for the best outcomes. We investigated NC's presenting features and associations with diagnostic delays.
Methods We manually reviewed medical records from US participants in the NC Registry (2007-2024). Baseline features were analyzed descriptively, and multivariable logistic regression was used to examine odds ratios for delays.
Results We analyzed 132 patients (median age 37 years). At presentation, 55% had metastatic disease and 64% had a thoracic primary. The median interval from symptom onset to diagnosis was 10 weeks (range, 1-165 weeks). The initial histopathologic diagnosis was poorly differentiated/squamous cell cancer in 52%, insufficient malignant cells in 14%, carcinoma in 12%, and NC in 22%. Immunohistochemistry (IHC) testing revealed NUT in 100%; 93% were keratin+, 88% p63+, 89% p40+, and 72% had Ki-67 ≥50%. IHC was used to diagnose NC in 79%. Nonthoracic primaries were associated with a longer time between symptom onset and NC diagnosis (odds ratio, 3.25). Of 32 patients who started treatment before diagnosis, 78% were on agents appropriate for NC. After a diagnosis of NC, 33% participated in clinical trials.
Conclusion NC almost always presents as squamous/poorly differentiated non–small cell lung or head and neck cancer. Overall, 78% of patients were initially diagnosed as non-NC. Efforts to raise awareness, recognition, and rapid diagnosis of NC by both oncologists and pathologists are critical if we are to improve outcomes.

Krutika Kuppalli, MD FIDSA @krutikakuppalli.bsky.social · 8mo ago

🚨 >50% of ID fellowships went unfilled—just as the need is surging. Currently on ID consults and seeing unprecedented volumes and an increasingly immunocompromised population at risk for life-threatening infections. I’m worried we’re heading toward fewer specialists when we need them most.

American Association for Cancer Research (AACR)@theaacr.bsky.social · 9mo ago

Alexander Drilon, Jolanta Grembecka, Jessica Jiyeong Lin, and Jia Luo will discuss "Translating Discoveries Toward New Therapies" in a plenary session at the AACR Conference on Fusion-Positive Cancers (January 13-15, 2026; Philadelphia). Learn more: buff.ly/3jO4l4j #AACRfusion26 @jia-luo.bsky.social

Dana-Farber Cancer Institute @danafarber.bsky.social · 10mo ago

@stolaney1.bsky.social addresses a full house during the #ESMO25 presidential discussion on Reshaping Density – Transforming Outcomes in High-Risk HER2+ Breast Cancer.

Dana-Farber News @danafarbernews.bsky.social · 10mo ago

Lung cancer research at #ESMO25: Chemotherapy combo boosts overall survival in patients with EGFR-mutant non-small cell lung cancer. @danafarber.bsky.social's Dr. Pasi Jänne presents the complete data from phase 3 FLAURA2 study. Press release ➡️bit.ly/47oV0hd

Dr. Pasi Jänne of Dana-Farber Cancer Institutes presents at #ESMO25.

Vijay G. Sankaran @bloodgenes.bsky.social · 10mo ago

www.nih.gov/news-events/...

Secretary Kennedy Swears in Dr. Anthony Letai as Director of the National Cancer Institute

Dr. Letai will serve as NCI’s 18th director.

nih.gov

Jia Luo, MD @jia-luo.bsky.social · 10mo ago

What a great throwback! Brings me back to middle school computer lab when - as the cool kids - we were using this little known search called "google" on our bright boxy blue iMacs when the standard at the time was Ask Jeeves

Carl Zimmer @carlzimmer.com · 11mo ago

A deep dive into the destruction of US cancer research by @jonathanmahler.bsky.social “It’s an absolutely unmitigated disaster,” a former top official at NIH told him. “It will take decades to recover from this, if we ever do.” Gift link: nyti.ms/48iH3Cr

nyti.ms

Jia Luo, MD @jia-luo.bsky.social · 11mo ago

What a fantastic IASLC WCLC25! Congrats to star resident (onc-to-be!) Dr Huang & We had a superb global multi-D discussion on ground glass/semisolid lung nodules - packed room in our last session of the day! TY chairs Drs Naidoo Opitz Malapelle & Noemi - feeling inspired 🙏 @iaslc.bsky.social

Paul Sax @paulsaxmd.bsky.social · 11mo ago

For us ID doctors, the CDC has been a rock. Data, guidelines, surveillance, travel advice -- all there, vetted by experts, referenced, reliable. Perfect? No. But watching its dismantling now breaks my heart. Some thoughts: blogs.jwatch.org/hiv-id-obser...

Watching the Chaos at the CDC -- with Sadness and Alarm

Throughout my career as an infectious diseases doctor, the CDC has been a rock-solid source. Need reliable data on an outbreak? The CDC. Need thoughtful, evidence-based guidelines? The CDC. Need an au...

blogs.jwatch.org

Jia Luo, MD @jia-luo.bsky.social · 11mo ago

🩻 Look forward to our interactive multidisciplinary lung nodules session @ IASLC WCLC 2025 meeting next week, September 6-9 in Barcelona It's been fantastic to plan our program with this group of experts spanning the 🗺️, meeting 6am (PT) - 11pm (AEST)! wclc.iaslc.org #lcsm @iaslc.bsky.social #WCLC25

E John Wherry @ejohnwherry.bsky.social · 12mo ago

vimeo.com/1103907156/4...

A World Without Academic Medicine 2025

This is "A World Without Academic Medicine 2025" by AAMC on Vimeo, the home for high quality videos and the people who love them.

vimeo.com

Jeremy Berg @jeremymberg.bsky.social · 12mo ago

New report from AAMC about clinical trials, other grants, and training www.aamc.org/about-us/mis...

Clinical trials and research training stalled as billions in NIH funds sit idle

Billions in NIH research funds remain unspent, stalling clinical trials, halting grants, and disrupting training for future scientists.

aamc.org

Dana-Farber Cancer Institute @danafarber.bsky.social · 12mo ago

Please join us in congratulating Alice Shaw, MD, PhD, on being named our next Chair of the Department of Medical Oncology. Learn more: bit.ly/45wiiQ6

Alice T. Shaw named Chair of Department of Medical Oncology at Dana-Farber Cancer Institute | Dana-Farber Cancer Institute

Alice T. Shaw, MD, PhD, was named Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute, in an announcement today.

bit.ly

Jia Luo, MD @jia-luo.bsky.social · 12mo ago

Fantastic to interview Dr. William Pao about his book "Breakthrough" with Dr. Jänne So inspiring for us to hear stories about resiliency and learning from failure in research to develop transformational medicines Special thanks to Sitara & the Chen-Huang Center #lcsm @danafarber.bsky.social

Photos of the Endowed Lecture interview with Dr Wiliam Pao, including Drs Luo, Jänne, Rotow, Barbie, Sitara and the in person crowd

Jia Luo, MD @jia-luo.bsky.social · 12mo ago

Excited to host drug developer extraordinaire Dr. William Pao at Dana-Farber Dr. Jänne and I will interview Dr. Pao tomorrow (Tuesday, August 12) about his book, Breakthrough, "a triumphant read about overcoming disease" www.simonandschuster.com/books/Breakt... @danafarbernews.bsky.social

Jia Luo, MD @jia-luo.bsky.social · 12mo ago

🩺 In NEJM, our interactive case on a common CC - evaluation of a patient with new pulmonary symptoms www.nejm.org/doi/full/10.... Congrats to star fellow Dr Joanne I. Hsu for leading & wonderful to learn from expert multi-D colleagues @anandvaidya17.bsky.social @harvardmed.bsky.social @nejm.org

NEJM.org@nejm.org · last yr.

A 59-year-old woman presented to the emergency department with a 1-week history of profound fatigue, nonproductive cough, confusion, and decreased oral intake. The night before presentation, she began to have chills and night sweats. Learn more and test your skills: nej.md/4mcUHuL

Interactive Medical Case
A Case of Crackles

An illustration of the patient coughing in bed and her husband caring for her

Jia Luo, MD @jia-luo.bsky.social · last yr.

Celebrating endings and new beginnings - it has been fantastic to have Dr Paoloni on our research team during his awarded American-Italian Cancer Foundation Research Fellowship grant! @danafarber.bsky.social @danafarbernews.bsky.social #lcsm

Research group dinner. From left to right: Dr Paoloni, Huang, Sara Walton, Justin Kim, Dr Luo, and Dr Pecci

Dr Paoloni (center) with Drs French and Luo

Jeremy Berg @jeremymberg.bsky.social · last yr.

New STAT story about multi-year funding. www.statnews.com/2025/07/29/n...

NIH is shrinking the number of research projects it funds due to a new Trump policy

NIH plans to shrink the share of grant applications it will award for the remainder of the fiscal year, in some cases by more than half.

statnews.com

Jia Luo, MD @jia-luo.bsky.social · last yr.

1/ In Clinical Cancer Research, we examined underdiagnosis of NUT carcinoma, an aggressive squamous lung, head and neck cancer, and found >75% are missed on standard of care testing (DNA panel NGS) 🫁 🗣️ doi.org/10.1158/1078... #medsky #oncsky #meded #lcsm #lungcancer @theaacr.bsky.social 🧵A thread:

Molecular characterization of NUT carcinoma: a report from the NUT carcinoma registry
Abstract
Purpose: NUT carcinoma (NC) is an underdiagnosed, poorly differentiated squamous cell cancer with a median survival of 6.7 months. Defined by NUTM1 fusions, NC enhances oncogene transcription, including MYC. We investigated the ability of standard next-generation sequencing (NGS) to identify NUTM1 fusions and describe additional molecular features of NC. Experimental Design: This study included 116 NC patients whose tumors underwent broad-panel NGS (>80 genes) of DNA, ctDNA, and/or RNA fusion sequencing between 2013-2024. NGS reports and medical records were manually reviewed. Results: Of 116 patients (median age 38, 40.5% female), 84.5% had DNA, 12.1% had ctDNA, and 51.7% had RNA fusion testing. In a subset of 100 patients with DNA/ctDNA testing, 92.9% (n=79/85) had <10 pack-years/never-smoking history, and 58.8% (n=47/80) had a BRD4::NUTM1 fusion. Median TMB was 1.0 mut/Mb (range 0.0-16.0; n=71 known), and 19.7% (n=13/66) had PD-L1 expression ≥1%. DNA, ctDNA, RNA fusion, NUT IHC, and NUTM1 FISH detected NC fusions in 21.6%, 21.4%, 83.9%, 100.0%, and 91.9% of tests, respectively. Co-occurring pathogenic mutations included oncogenes PIK3CA, RET, FGFR3, and tumor suppressors ATM and BRCA1 (n=1 each). Secondary genes altered in >5% of NCs included LRP1B (10.4%), MLL2/KMT2D (8.0%), and FAT1 (5.5%); common pathways with mutated genes were epigenetic (57.0%), cell cycle (26.0%), and DNA repair (24.0%). Conclusions: Standard DNA NGS detects less than a quarter of NUT carcinomas; RNA-based fusion testing, or NUT IHC/NUTM1 FISH, should be routine for suspected NC. NCs are enriched in co-occurring epigenetic, cell cycle, and DNA repair alterations, warranting further evaluation.

Jia Luo, MD @jia-luo.bsky.social · last yr.

🌟 Some great colleagues, including Dr Julia Rotow, and I will be discussing the latest practice changing data in oncology @ Best of ASCO Boston July 26-27! Program and registration horizoncme.com/best-of-asco... #oncsky @ascocancer.bsky.social @danafarbernews.bsky.social @danafarber.bsky.social

This two-day conference is an Official Annual Meeting Review of ASCO25, featuring expert faculty who will review findings, discuss potential impacts on the current standard of care, and apply the results within the clinical context of a patient case.

Jia Luo, MD @jia-luo.bsky.social · last yr.

Encouraging news from the US FDA - a fast track designation - for our patients with NUT carcinoma! It's been incredible team science from the preclinical, to the iterative FIH translation, to our ongoing NIH-funded NCI CTEP/ETCTN clinical trial #oncsky #lcsm

OncLive@onclive.bsky.social · last yr.

FDA Grants Fast Track Status to ZEN-3694 Plus Abemaciclib for Unresectable or Metastatic NUT Carcinoma #oncology www.onclive.com/view/fda-gra...

Nandita Garud @nanditagarud.bsky.social · last yr.

I am seeking a postdoc for my group at UCLA. We work at the intersection of population genetics x microbiome (garud.eeb.ucla.edu). If interested, please message me!

Garud Lab

garud.eeb.ucla.edu

Nature @nature.com · last yr.

These members of the NIH Council of Councils are voicing serious concerns about NIH grant terminations, restructure, and budget cuts go.nature.com/46Vr8t2

Protect the integrity of the US National Institutes of Health

Letter to the Editor

go.nature.com

Jia Luo, MD @jia-luo.bsky.social · last yr.

Outstanding commencement speech by Sandra Oh fit for these times on living with discomfort. Well worth the watch. youtu.be/P7TYeFy0JtA?...

2025 Commencement Address by Sandra Oh

YouTube video by Dartmouth

youtu.be

Jia Luo, MD @jia-luo.bsky.social · last yr.

🗺️ 🫁 Thrilled to work with and learn from this multi-D international panel of lung cancer experts We’ve got a fantastic interactive discussion on pulmonary nodules planned - Tues Sept 9 @ IASLC #WCLC25 in Barcelona Join us! / Register: wclc.iaslc.org @iaslc.bsky.social #lcsm #medsky

Zoom picture of multidisciplinary panel of experts on lung cancers

Jia Luo, MD @jia-luo.bsky.social · last yr.

Celebrating a win - when a fantastic CRC in your group achieves their dream of going to medical school!

Larry Levitt @larrylevitt.bsky.social · last yr.

Republicans are poised to pass the biggest cuts in health coverage ever. @nytopinion.nytimes.com www.nytimes.com/2025/07/01/o...

Opinion | We’ve Never Seen Health Care Cuts This Big

nytimes.com